NASDAQ OMX

NABUFIT Announces Defending Double Olympic Champion Mo Farah as Brand Ambassador

Del

OREM, Utah, 2016-11-10 12:00 CET (GLOBE NEWSWIRE) --

NABUFIT Global ApS, the wholly owned Danish subsidiary of NABUFIT Global, Inc. (OTCQB:NBFT), a ground breaking new training portal that enhances your workout by providing expert advice from professional trainers, health experts and international sports stars, today announced that British athletics legend Mohamed Muktar Jama “Mo” Farah (Mo Farahhas joined the company as a key brand ambassador where he will help position the NABUFIT brand globally in a 3-year agreement. Mo Farah, who has over 2 million social media followers on FacebookInstagram and Twitter, will contribute with mentoring workout videos to motivate and inspire people to live a healthier and more active life through NABUFIT’s wellness platform and app.

NABUFIT’s agreement with the legendary British distance runner Mo Farah represents its next Global Brand Ambassador to be included in its online fitness platform. Mo Farah is the most successful British track athlete ever after winning the 5k/10k double at the Olympic Games in London in 2012 and again at the Rio 2016 Olympic Games. That has also made him the second ever athlete to defend the double in Olympic history. Additionally, Mo Farah holds the double in the athletics World Championships where he won the 5k/10k double in 2013 and 2015. With a total of five European Athletics Championship gold medals, Mo Farah has written history yet again being the championships’ most successful individual athlete.

As one of the sports stars and Ambassadors of NABUFIT, Mo Farah will, along with his other counterparts, provide exclusive training programs, interviews and help motivate and inspire people to live a more active and healthy life.

"I am very honored to be part of the NABUFIT lineup of legends and I cannot wait to start recording the workouts and to be a part of the success NABUFIT is already experiencing,” says Mo Farah, global brand ambassador of NABUFIT.

Mo Farah joins NABUFIT at a time of significant growth of the Company. NABUFIT has reached more than 200,000 downloads in more than 180 countries in the first three months on the market. NABUFIT continues to show significant traction in developing a world-class online fitness portal by expanding into new markets as well as adding sports stars with new features and unique content. NABUFIT's current roster of brand ambassadors includes agreements with F.C. Barcelona soccer player Neymar Jr., the former best goalkeeper in the world Peter Schmeichel and the table tennis player and Olympic medal winner Michael Maze.

With the signing of the British athletics star, Mo Farah, NABUFIT continues to position its fitness platform on a global scale to reach and inspire a broad audience. NABUFIT welcomes a legend who for the last 10 years has made a fantastic contribution to international athletics.

"We are very proud to welcome Mo Farah to our team of international sports stars and legends,” says Brian Palm Svaneeng Mertz, CEO of NABUFIT. He has shown an extraordinary commitment to his sport and his fans, and that now includes providing unique content to the NABUFIT platform. With his great values, positive attitude and endurance, Mo Farah inspires millions of people, which makes him a perfect match for NABUFIT.”

NABUFIT app users can expect to see Mo Farah featured in the app in January 2017. The app is available for download in Apple Store and Google Play.

About NABUFIT Global Inc.

NABUFIT Global, Inc. (www.nabufit.com) is a US public company. NABUFIT is an online fitness platform for health and well-being through physical exercises, nutrition and lifestyle. The platform offers an interactive, customized experience founded on the workouts and participation of Sports Stars such as Neymar Jr., Peter Schmeichel, Michael Maze and many more to come. The development headquartered in Denmark is developing an online fitness platform and a mobile application that connects to existing and future monitoring devices (wearables etc.).

NABUFIT is working in a space with competitors like NIKEUnder Armour who owns Endomondo, MyFitnessPal and more. 

Forward-Looking Statements

Statements about the expected timing, and all other statements in this press release, other than historical facts, constitute forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date hereof and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those projected. A number of the matters discussed herein that are not historical or current facts deal with potential future circumstances and developments that may or may not materialize. This press release speaks only as of its date, and except as required by law, we disclaim any duty to update.

         Contact: NABUFIT Global, Inc.
         
         Brian Mertz
         CEO
         +45 23903300
         bm@nabufit.com
         
         Bob Bench
         CFO
         +1 801-362-2115
         bobbench@nabufit.com

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53Pressemelding

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc

Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42Pressemelding

NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq

Colliers International Expands in Washington, D.C.18.10.2017 14:30Pressemelding

Acquisition of Beltway Real Estate Services Firm Strengthens Ongoing Commitment to the Region TORONTO and WASHINGTON, Oct.  18, 2017  (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI)(TSX:CIGI) announced today the acquisition of leading tenant representation advisory firm Serten Advisors. With its office in Tysons Corner, the firm serves global, national, and regional clients with a highly skilled and experienced team of professionals that have more than 100 years of combined experience. "This strategic acquisition positions Colliers to gain additional market share and win new business in the vibrant and competitive Suburban DC markets," said Marty Pupil, Colliers International President | U.S. Brokerage. "Adding Steve and Paul and the rest of their talented leadership team to our existing group of professionals in the region will further position Colliers as the commercial real estate services firm of

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC18.10.2017 14:00Pressemelding

InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs.  The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC.  Anti-fibrotic therapi

Kofax Wins "Most Innovative Solution for Banking Customer Authentication" Award for Third Consecutive Year18.10.2017 08:00Pressemelding

Grand Prix Banque & Innovation Honor Recognizes Kofax Mobile ID Customer Onboarding Solution and its Anti-Fraud Capabilities IRVINE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Kofax ®, a leading provider of software to simplify and transform the First Mile(TM) of business, today announced that Kofax Mobile ID(TM) has won "Most Innovative Solution for Banking Customer Authentication" in the 2017 Grand Prix Banque & Innovation Awards in Paris, France. Now in its fourth year, the Awards identify excellence and innovation in the banking sector. The program acknowledges technology companies that have launched and implemented the most outstanding banking-related software solutions, initiatives and projects in France over the past twelve months. This award highlights the new facial recognition and ID verificationfeatures of Kofax Mobile ID that determine the authenticity and validity of identification documents and their holders.  

World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer18.10.2017 06:25Pressemelding

YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference from the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new advancements surrounding the discovery of PD-1 and PD-L1, including a discussion from the researcher credited with discovering PD-1, as well as interventions to prevent lung cancer and improve quality of life for lung cancer patients. Innovations in lung cancer treatment linked to the discovery of PD-1 Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared an update on how PD-1 blockers have been widely used to treat many types of cancers. After decades of study, research into PD-1 has led to breakthrough immunotherapy treatments that are being hailed as a "penicillin moment" in cancer treatment. "I believe that, just as a number of antibiotics developed in the wake of the discovery of penicillin now p

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom